GO
Loading...

Momenta Pharmaceuticals Inc

More

  • Nasdaq stocks posting largest percentage increases Monday, 20 Apr 2015 | 1:17 PM ET

    XBiotech Inc. rose 20.3 percent to $31.50. Voltari Corp. rose 19.7 percent to $10.38. Dicerna Pharmaceuticals rose 14.3 percent to $22.03.

  • The generic, called Glatopa, is made by Sandoz, a unit of Swiss drug company Novartis AG, and U.S.-based Momenta Pharmaceuticals. The Food and Drug Administration approved the drug Thursday. But Teva Pharmaceutical Industries, which makes Copaxone, has said it expects generic versions of the drug to go on sale in the U.S. in September.

  • The copied 20 mg version of the blockbuster drug, submitted by Sandoz, a unit of Swiss drugmaker Novartis AG, can be labeled "substitutable" for Copaxone, meaning that prescriptions for the brand-name drug can be automatically switched to the generic. The generic drug, called Glatopa, was developed collaboratively by Novartis and Momenta Pharmaceuticals Inc...

  • Nasdaq stocks posting largest percentage increases Thursday, 16 Apr 2015 | 1:29 PM ET

    Identive Inc. rose 38.5 percent to $12.40. Travelzoo Inc. rose 32.0 percent to $13.57. Netflix Inc. rose 18.2 percent to $562.05.

  • April 16- Momenta Pharmaceuticals Inc said the U.S. Food and Drug Administration approved the first generic version of Teva Pharmaceuticals Industries Ltd's top-selling multiple sclerosis drug, Copaxone. The agency cleared the application for the 20 mg version of the blockbuster drug, submitted by Momenta's partner Sandoz, a unit of Swiss drugmaker...

  • *Q4 adjusted EPS $1.31, in line with expectations. TEL AVIV, Feb 5- Teva Pharmaceutical Industries is ready to return to making acquisitions, it said on Thursday, after a year of focusing on costs under its new chief executive. The company posted fourth-quarter earnings of $1.31 per diluted share, excluding one-time items, against $1.42 a year earlier.

  • WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries Ltd can still benefit from patent protection for top-selling multiple sclerosis drug Copaxone, dealing a blow to generic drugmakers looking to market a cheaper rival product. In a 7-2 vote, the justices sent the case back to the U.S. Court of Appeals for the Federal...

  • TEL AVIV, Dec 11- Teva Pharmaceutical Industries forecast 2015 revenue below analysts' expectations, due to adverse foreign exchange moves and generic competition for its best-selling multiple sclerosis treatment Copaxone. There are two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's Sandoz Inc and Momenta...

  • Biotech's a Buy, but Hold Off on HMOs: Fund Manager Wednesday, 9 Jan 2013 | 2:02 PM ET
    'Rare Good News' on Health Care Retirement Savings: Study

    Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.

  • 13 Biotech Stock Predictions for 2013 Wednesday, 2 Jan 2013 | 7:55 AM ET
    medicare.jpg

    TheStreet.com offers up 13 biotech predictions for 2013.

  • Stocks to Watch: BUD, STZ, WMT & More Monday, 25 Jun 2012 | 12:47 PM ET
    market-insider-stocks-to-watch-200.jpg

    Take a look at some of Monday's midday movers:

  • What's Shaking: Monday's Early Movers Monday, 30 Jan 2012 | 8:28 AM ET
    market-insider-stocks-to-watch-200.jpg

    Take a look at some of Monday morning's early movers:

  • Mad Mail: MedAssets, Momenta Pharmaceuticals and More Saturday, 26 Mar 2011 | 12:45 PM ET

    When someone calls about a stock Cramer doesn't know, he does his homework and follows up.

  • The Lightning Round is extended in this CNBC.com exclusive feature.

  • Small-cap companies with an almost 400% return Thursday, 28 Aug 2008 | 9:53 AM ET

    So far this year, the Russell 2000 index of small-cap companies continues to outperform the Dow, and the S&P 500.  While most of these companies average only a $1 billion dollar market capitalization, some of their returns are proving resilient to an economic slowdown. 

  • Winners & Losers: Retailers Rule Tuesday, 6 Nov 2007 | 5:58 PM ET

    Rising oil prices have not stopped consumers from going to the mall.  Retailer Guess is enjoying a 15% surge in their stock price. The clothing company reported better than expected revenue.